Edgar Filing: CAVAZZA PAOLO

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Essetifin SPA

2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [SNGX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
_____ Officer (give title below)	__X__ Other (specify below)
Former 10% Owner

(Last)

(First)

(Middle)

VIA SUDAFRICA, 20

3. Date of Earliest Transaction (Month/Day/Year)
11/29/2017

(Street)

ROME, L6 00144

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/29/2017		S		271,140 ⁽¹⁾	D	$ 2.12	0 ⁽²⁾ ⁽³⁾	I ⁽³⁾ ⁽⁶⁾	Indirect ⁽³⁾
Common Stock	11/29/2017		P		271,140 ⁽¹⁾	A	$ 2.12	271,140 ⁽²⁾ ⁽³⁾	D ⁽³⁾ ⁽⁶⁾
Common Stock	11/29/2017		S		5,954 ⁽¹⁾	D	$ 2.12	0 ⁽⁴⁾	I ⁽⁴⁾ ⁽⁶⁾	Indirect ⁽⁴⁾
Common Stock	11/29/2017		P		5,954 ⁽¹⁾	A	$ 2.12	277,094 ⁽⁴⁾	D ⁽⁴⁾ ⁽⁶⁾
Common Stock	11/29/2017		S		16,416 ⁽¹⁾	D	$ 2.12	0 ⁽⁵⁾	I ⁽⁵⁾ ⁽⁶⁾	Indirect ⁽⁵⁾
Common Stock	11/29/2017		P		16,416 ⁽¹⁾	A	$ 2.12	293,510 ⁽⁵⁾	D ⁽⁵⁾ ⁽⁶⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Essetifin SPA VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
CAVAZZA PAOLO VIA TESSERETE, 10 LUGANO, V8 00000				Former 10% Owner
Leadiant Biosciences, Inc. 9841 WASHINGTONIAN BLVD., SUITE 500 GAITHERSBURG, MD 20878				Former 10% Owner
Cavazza Enrico VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
Cavazza Francesca VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
Cavazza Silvia VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner
Cavazza Preta Martina VIA SUDAFRICA, 20 ROME, L6 00144				Former 10% Owner

Signatures

Essetifin S.p.A. By: /s/ Marino Zigrossi		11/30/2017
^**Signature of Reporting Person		Date
/s/ Fabio Poma for Paolo Cavazza by power of attorney		11/30/2017
^**Signature of Reporting Person		Date
Leadiant Biosciences, Inc. By: /s/ Marino Zigrossi		11/30/2017
^**Signature of Reporting Person		Date
/s/ Marino Zigrossi for Enrico Cavazza by power of attorney		11/30/2017
^**Signature of Reporting Person		Date
/s/ Marino Zigrossi for Francesca Cavazza by power of attorney		11/30/2017
^**Signature of Reporting Person		Date
/s/ Marino Zigrossi for Silvia Cavazza by power of attorney		11/30/2017
^**Signature of Reporting Person		Date
/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney		11/30/2017
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split.
(2)	This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer.
(3)	Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock.
(4)	Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin.
(5)	Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.
(6)	Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.
Remarks: Exhibit List: Exhibit 24.1 - Power of Attorney; Exhibit 99.1 - Joint Filers' Signatures

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.